PURPOSE: Office-based treatment of opioid addiction with a combination of buprenorphine and naloxone was approved in 2002. Efficacy of this treatment in non-research clinical settings has not been studied. We examined the efficacy and practicality of buprenorphine-naloxone treatment in primary care settings. METHODS: We studied a cohort of 99 consecutive patients enrolled in buprenorphine-naloxone treatment for opioid dependence at 2 urban primary care practices: a hospital-based primary care clinic, and a primary care practice in a free-standing neighborhood health center. The primary outcome measure was sobriety at 6 months as judged by the treating physician based on periodic urine drug tests, as well as frequent physical examinations and questioning of the patients about substance use. RESULTS: Fifty-four percent of patients were sober at 6 months. There was no significant correlation between sobriety and site of care, drug of choice, neighborhood poverty level, or dose of buprenorphine-naloxone. Sobriety was correlated with private insurance status, older age, length of treatment, and attending self-help meetings. CONCLUSIONS: Opioid-addicted patients can be safely and effectively treated in non-research primary care settings with limited on-site resources. Our findings suggest that greater numbers of patients should have access to buprenorphine-naloxone treatment in nonspecialized settings.
PURPOSE: Office-based treatment of opioid addiction with a combination of buprenorphine and naloxone was approved in 2002. Efficacy of this treatment in non-research clinical settings has not been studied. We examined the efficacy and practicality of buprenorphine-naloxone treatment in primary care settings. METHODS: We studied a cohort of 99 consecutive patients enrolled in buprenorphine-naloxone treatment for opioid dependence at 2 urban primary care practices: a hospital-based primary care clinic, and a primary care practice in a free-standing neighborhood health center. The primary outcome measure was sobriety at 6 months as judged by the treating physician based on periodic urine drug tests, as well as frequent physical examinations and questioning of the patients about substance use. RESULTS: Fifty-four percent of patients were sober at 6 months. There was no significant correlation between sobriety and site of care, drug of choice, neighborhood poverty level, or dose of buprenorphine-naloxone. Sobriety was correlated with private insurance status, older age, length of treatment, and attending self-help meetings. CONCLUSIONS:Opioid-addictedpatients can be safely and effectively treated in non-research primary care settings with limited on-site resources. Our findings suggest that greater numbers of patients should have access to buprenorphine-naloxone treatment in nonspecialized settings.
Authors: P G O'Connor; A H Oliveto; J M Shi; E G Triffleman; K M Carroll; T R Kosten; B J Rounsaville; J A Pakes; R S Schottenfeld Journal: Am J Med Date: 1998-08 Impact factor: 4.965
Authors: D C Des Jarlais; S R Friedman; J L Sotheran; J Wenston; M Marmor; S R Yancovitz; B Frank; S Beatrice; D Mildvan Journal: JAMA Date: 1994-01-12 Impact factor: 56.272
Authors: Olga Rass; Annie Umbricht; George E Bigelow; Eric C Strain; Matthew W Johnson; Miriam Z Mintzer Journal: Psychol Addict Behav Date: 2014-11-03
Authors: Adam J Gordon; David A Fiellin; Peter D Friedmann; Marc N Gourevitch; Kevin L Kraemer; Julia H Arnsten; Richard Saitz Journal: J Gen Intern Med Date: 2008-10-02 Impact factor: 5.128
Authors: Roger D Weiss; Margaret L Griffin; David E Marcovitz; Blake T Hilton; Garrett M Fitzmaurice; R Kathryn McHugh; Kathleen M Carroll Journal: J Clin Psychiatry Date: 2019-03-26 Impact factor: 4.384